Testimonials
The election is over, and with it also comes the end (for now) of the seemingly endless text messages, mail, dinnertime phone calls, and TV and social media ads. But there are many questions as to what comes next and not a lot of answers just yet. Listen to "Unscripted" The AMCP Podcast, for updates from the new Trump administration and Congress's health policy agenda from AMCP.
AMCP 2024 AAO Report
AMCP's feature annual report explores how professionals in managed care pharmacy work diligently to facilitate appropriate access to prescription treatments while remaining mindful of rising costs. It discusses key areas of focus such as pharmacy benefit design, formulary management, clinical programs, quality, safety and promoting affordability of medicines.
AMCP eModel is the ultimate tool for communication of health economic models and value evidence. Find out more about this tech partnership and this health economic modeling platform to support the exchange of clinical and economic information between manufacturers and payers.
AMCP partners with FormularyDecisions to enhance information sharing and formulary decision-making by creating a platform for current, credible, and compliant information exchange between life science companies and active, qualified healthcare decision-makers.
Featured
-
Health Information Technology Resources
-
Digital Therapeutics Resources
-
Health Disparities Resources
-
Value-Based Contracts Resources
Meetings Proceedings & Findings
View More
Latest News & Resources
Health plans, employers and government-sponsored health care programs are focusing their attention on optimizing patient outcomes through the use of medications that have established evidence of efficacy and safety, while providing the highest value.
Disease management is the concept of reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care. Disease management programs are designed to improve the health of persons with chronic conditions and reduce associated costs from avoidable complications by identifying and treating chronic conditions more quickly and more effectively, thus slowing the progression of those diseases.
Congress passed the Health Insurance Portability and Accountability Act (HIPAA) in 1996. Within that Act are privacy provisions with which covered entities (including all health plans, health care providers and health care clearinghouses [e.g. PBMs] that transmit any health information in electronic form must comply. HIPAA rules provide guidance to covered entities about how to comply with the Act.
The purpose of this paper is to explain how managed care organizations (MCOs) are able to secure lower drug prices from pharmaceutical manufacturers as part of an effort to control drug expenditures.
AMCP believes that payors must have the flexibility to use mail service delivery of prescription drugs as a component of their prescription drug benefit.
Press Release: Focusing on what’s best for the patient, leveraging technology to perform real-time benefit checks, and developing trust and transparency among stakeholders are some of the suggestions to emerge from AMCP’s recent Partnership Forum on “Optimizing Prior Authorization for Appropriate Medication Selection.”
Common managed care terms and their meaning.
Managed care pharmacy and prescription drug coverage is a growing part of the American health care sector. AMCP launched the annual Access, Affordability, and Outcomes report to raise awareness of the existence, prevalence, and importance of managed care pharmacy.
Learn how managed care pharmacy can play a vital role in patient-centered medical homes.
The concise policy statements included in the AMCP Practice Positions are part of an ongoing process that documents the AMCP's position on professional and practice issues. These practice positions will serve to aid AMCP members in describing their roles and serves as the basis for AMCP’s public policy statements. they also aid in advancing AMCP’s positions to target audiences. These policy statements, approved by AMCP’s Board of Directors, cover a wide range of pharmacy and practice issues and have been derived from existing AMCP Legislative & Regulatory Positions, Medicare Part D Series, Concept Papers, and other policy statements.
List of Forum topics for 2019. For additional information, contact: AMCP’s Strategic Alliances & Corporate Services Office | busdevelopment@amcp.org | (703) 684-2616
AMCP letter to Congressional Leadership asking for the inclusion of 42 CFR Part 2 provisions and Medicare fraud, waste and abuse protections in a final opioid conference report
